Patents by Inventor Robert Gersch

Robert Gersch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANGIOGENIC CONDITIONING TO ENHANCE CARDIAC CELLULAR REPROGRAMMING OF FIBROBLASTS OF THE INFARCTED MYOCARDIUM
    Publication number: 20220088143
    Abstract: Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).
    Type: Application
    Filed: December 9, 2021
    Publication date: March 24, 2022
    Inventors: Ronald G. Crystal, Todd K. Rosengart, Robert Gersch, Megumi Mathison
  • ANGIOGENIC CONDITIONING TO ENHANCE CARDIAC CELLULAR REPROGRAMMING OF FIBROBLASTS OF THE INFARCTED MYOCARDIUM
    Publication number: 20190358297
    Abstract: Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).
    Type: Application
    Filed: August 9, 2019
    Publication date: November 28, 2019
    Inventors: Ronald G. Crystal, Todd K. Rosengart, Robert Gersch, Megumi Mathison
  • Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium
    Patent number: 10383916
    Abstract: Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: August 20, 2019
    Assignees: CORNELL UNIVERSITY, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Ronald G. Crystal, Todd K. Rosengart, Robert Gersch, Megumi Mathison